Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sensus Healthcare to Host First Quarter 2017 Financial Results and Business Update Conference Call on May 4, 2017

SRTS

PR Newswire

BOCA RATON, Fla., April 27, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), announced today that management will hold a conference call beginning at 4:30 p.m. Eastern Time on Thursday, May 4, 2017 to discuss the financial results for the first quarter of 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

To access the conference call, the dial-in numbers are 1-877-870-4263 (U.S. Toll Free), 1-412-317-0790 (International) and 1-855-669-9657 (Canada Toll Free). Please ask the operator to be connected to the Sensus Healthcare call.

Following the conclusion of the conference call, a replay will be available through May 11, 2017 and can be accessed by dialing 1-877-344-7529 (U.S. Toll Free), 1-412-317-0088 (International), and 1-855-669-9658 (Canada Toll Free). All listeners should provide the replay passcode 10106354. The call will also be archived on the Company website for a time at http://www.sensushealthcare.com

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For further information, please visit http://www.sensushealthcare.com

Contacts:

Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sensus-healthcare-to-host-first-quarter-2017-financial-results-and-business-update-conference-call-on-may-4-2017-300446772.html

SOURCE Sensus Healthcare



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today